Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment

References

• Aasheim HC, Patzke S, Hjorthaug HS, Finne EF. 2005. Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis. Biochim Biophys Acta 1723:1–7
   PubMed Web of Science ®Google Scholar
• Alemán JO, Farooki A, Girotra M. 2014. Effects of tyrosine kinase inhibition on bone metabolism: Untargeted consequences of targeted therapies. Endocr Relat Cancer 21:R247–R259
   PubMed Web of Science ®Google Scholar
• Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, et al. 2014. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest 124:2037–2049
   Web of Science ®Google Scholar
• Arvanitis D, Davy A. 2008. Eph/ephrin signaling: Networks. Genes Dev 22:416–429
   PubMed Web of Science ®Google Scholar
• Arvanitis DN, Davy A. 2012. Regulation and misregulation of Eph/ephrin expression. Cell Adh Migr 6:131–137
   PubMed Web of Science ®Google Scholar
• Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, et al. 2012. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765–780
   PubMed Web of Science ®Google Scholar
• Boyd AW, Bartlett PF, Lackmann M. 2014. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 13:39–62
   Google Scholar
• Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, et al. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21:7011–7026
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, et al. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118:64–78
   PubMed Web of Science ®Google Scholar
• Bruckner K, Pasquale EB, Klein R. 1997. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275:1640–1643
   PubMed Web of Science ®Google Scholar
• Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. 2002. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62:2840–2847
   PubMed Web of Science ®Google Scholar
• Carvalho RF, Beutler M, Marler KJ, Knoll B, Becker-Barroso E, Heintzmann R, Ng T, Drescher U. 2006. Silencing of EphA3 through a cis interaction with ephrinA5. Nat Neurosci 9:322–330
   Google Scholar
• Chen FY, Yan JJ, Yi HX, Hu FQ, Du YZ, Yuan H, You J, Zhao MD. 2014. TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting. Int J Nanomedicine 9:4597–4608
   Web of Science ®Google Scholar
• Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, et al. 2003. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5:445–456
   PubMed Web of Science ®Google Scholar
• Coffman KT, Hu M, Carles-Kinch K, Tice DA, Donacki N, Munyon K, Kifle G, et al. 2003. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 63:7907–7912
   PubMed Web of Science ®Google Scholar
• Coulthard MG, Duffy S, Down M, Evans B, Power M, Smith F, Stylianou C, et al. 2002. The role of the Eph–ephrin signalling system in the regulation of developmental patterning. Int J Dev Biol 46:375–384
   PubMed Web of Science ®Google Scholar
• Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238–248
   PubMed Web of Science ®Google Scholar
• Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, et al. 2013. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol 85:507–513
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. 2004. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 320:1096–1102
   PubMed Web of Science ®Google Scholar
• Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. 1995. Protein B61 as a new growth factor: Expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 55:2528–2532
   PubMedGoogle Scholar
• Edwards CM, Mundy GR. 2008. Eph receptors and ephrin signaling pathways: A role in bone homeostasis. Int J Med Sci 5:263–272
   Google Scholar
• Egea J, Klein R. 2007. Bidirectional Eph–ephrin signaling during axon guidance. Trends Cell Biol 17:230–238
   PubMed Web of Science ®Google Scholar
• Falivelli G, Lisabeth EM, Rubio de la Torre E, Perez-Tenorio G, Tosato G, Salvucci O, Pasquale EB. 2013. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS One 28:e81445
   Google Scholar
• Fox BP, Kandpal RP. 2011. A paradigm shift in EPH receptor interaction: Biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines. Cancer Genomics Proteomics 8:185–193
   Google Scholar
• Freywald A, Sharfe N, Roifman CM. 2002. The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1. J Biol Chem 277:3823–3828
   PubMed Web of Science ®Google Scholar
• Graves LM, Duncan JS, Whittle MC, Johnson GL. 2013. The dynamic nature of the kinome. Biochem J 450:1–8
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. 2004. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 4:361–370
   PubMed Web of Science ®Google Scholar
• Gu C, Park S. 2001. The EphA8 receptor regulates integrin activity through p110γ phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol Cell Biol 21:4579–4597
   PubMed Web of Science ®Google Scholar
• Gurniak CB, Berg LJ. 1996. A new member of the Eph family of receptors that lacks protein tyrosine kinase activity. Oncogene 13:777–786
   PubMedGoogle Scholar
• Himanen JP. 2012. Ectodomain structures of Eph receptors. Semin Cell Dev Biol 23:35–42
   PubMed Web of Science ®Google Scholar
• Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T. 1996. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 383:722–725
   PubMed Web of Science ®Google Scholar
• Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, et al. 2008. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367–9374
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, et al. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132
   PubMed Web of Science ®Google Scholar
• Keane N, Freeman C, Swords R, Giles FJ. 2012. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol 5:325–340
   PubMed Web of Science ®Google Scholar
• Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS. 2006. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4–EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 107:2330–2338
   PubMed Web of Science ®Google Scholar
• Kilpatrick TJ, Brown A, Lai C, Gassmann M, Goulding M, Lemke G. 1996. Expression of the Tyro4/Mek4/Cek4 gene specifically marks a subset of embryonic motor neurons and their muscle targets. Mol Cell Neurosci 7:62–74
   PubMedGoogle Scholar
• Knapp S, Sundström M. 2014. Recently targeted kinases and their inhibitors – The path to clinical trials. Cur Opin Pharmacol 17C:58–63
   Google Scholar
• Koolpe M, Dail M, Pasquale EB. 2002. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 277:46974–46979
   PubMed Web of Science ®Google Scholar
• Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS. 2010. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 176:2029–2038
   PubMed Web of Science ®Google Scholar
• Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, et al. 2007. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083–1091
   Google Scholar
• Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, et al. 2009. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736–3745
   PubMed Web of Science ®Google Scholar
• Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, et al. 2006. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279–293
   PubMed Web of Science ®Google Scholar
• Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, et al. 2006. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98:1558–1570
   PubMed Web of Science ®Google Scholar
• Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, et al. 2009. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101:1193–1205
   PubMed Web of Science ®Google Scholar
• Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, et al. 2010. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16:2562–2570
   PubMed Web of Science ®Google Scholar
• Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, et al. 2010. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6:291–299
   PubMed Web of Science ®Google Scholar
• Lisabeth EM, Fernandez C, Pasquale EB. 2012. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochem 51:1464–1475
   PubMedGoogle Scholar
• Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, Wen Q, An R. 2014. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol 41:450–456
   Google Scholar
• Liu Y, Yu C, Qiu Y, Huang D, Zhou X, Zhang X, Tian Y. 2012. Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo. J Cancer Res Clin Oncol 138:195–202
   Google Scholar
• Lu CY, Yang ZX, Zhou L, Huang ZZ, Zhang HT, Li J, Tao KS, Xie BZ. 2013. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Rep 30:2179–2186
   Google Scholar
• Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Grey JW, McCormick F. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8:111–118
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marmé D, Augustin HG. 2004. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6:248–257
   PubMed Web of Science ®Google Scholar
• Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, et al. 2006. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 119:1236–1248
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Iwata N, Ito M, Shimoyama M, Nagata A, Chihara K, Takai S, Matsui T. 1997. Expression of a kinase-defective Eph-like receptor in the normal human brain. Biochem Biophys Res Commun 235:487–492
   PubMed Web of Science ®Google Scholar
• Mellitzer G, Xu Q, Wilkinson DG. 1999. Eph receptors and ephrins restrict cell intermingling and communication. Nature 400:77–81
   PubMed Web of Science ®Google Scholar
• Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, Jarnes L, et al. 2006. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 103:3153–3158
   PubMed Web of Science ®Google Scholar
• Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, et al. 2009. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16:9–20
   PubMed Web of Science ®Google Scholar
• Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. 2010. Structure–activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49:6687–6695
   PubMed Web of Science ®Google Scholar
• Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H. 2000. Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6. FEBS Lett 466:169–174
   Google Scholar
• Nagano K, Kanasaki S, Yamashita T, Maeda Y, Inoue M, Higashisaka K, Yoshioka Y, et al. 2013. Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Med 2:972–977
   Google Scholar
• Noberini R, Lamberto I, Pasquale EB. 2012. Targeting Eph receptors with peptides and small molecules: Progress and challenges. Semin Cell Dev Biol 23:51–57
   Google Scholar
• Noren NK, Foos G, Hauser CA, Pasquale EB. 2006. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8:815–825
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2005. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462–475
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2008. Eph–ephrin bidirectional signaling in physiology and disease. Cell 133:38–52
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2010. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10:165–180
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lin SF. 2000. The protein tyrosine kinase family of the human genome. Oncogene 19:5548–5557
   PubMed Web of Science ®Google Scholar
• Rutkowski R, Mertens-Walker I, Lisle JE, Herington AC, Stephenson SA. 2012. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. Int J Cancer 131:E614–E624
   Google Scholar
• Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, et al. 2009. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113:254–263
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, et al. 2010. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9:2377–2388
   PubMed Web of Science ®Google Scholar
• Stephenson S, Douglas EL, Mertens-Walker I, Lisle JE, Maharaj MSN, Herington AC. Anti-tumor effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. (in press)
   Google Scholar
• Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, et al. 2009. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 174:1492–1503
   PubMedGoogle Scholar
• Tandon M, Vemula SV, Mittal SK. 2011. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Therap Targ 15:31–51
   PubMed Web of Science ®Google Scholar
• Truitt L, Freywald A. 2011. Dancing with the dead: Eph receptors and their kinase-null partners. Biochem Cell Biol 89:115–129
   PubMedGoogle Scholar
• Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A. 2010. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res 70:1141–1153
   PubMed Web of Science ®Google Scholar
• Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, et al. 2014. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470–4481
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, et al. 1999. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 41:275–280
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. 2003. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162:1037–1042
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129–3140
   PubMed Web of Science ®Google Scholar
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, et al. 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509
   PubMed Web of Science ®Google Scholar
• Wykosky J, Gibo DM, Debinski W. 2007. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 6:3208–3218
   PubMed Web of Science ®Google Scholar
• Xi HQ, Wu XS, Wei B, Chen L. 2012. Aberrant expression of EphA3 in gastric carcinoma: Correlation with tumor angiogenesis and survival. J Gastroenterol 47:785–794
   Google Scholar
• Xi HQ, Zhao P. 2011. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64:498–503
   Google Scholar
• Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, et al. 2005a. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 11:4305–4315
   PubMed Web of Science ®Google Scholar
• Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, et al. 2005b. EphB4 expression and biological significance in prostate cancer. Cancer Res 65:4623–4632
   PubMed Web of Science ®Google Scholar
• Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, et al. 2006. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25:769–780
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Hikita H, Kohga K, Uemura A, et al. 2008. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother 57:1861–1869
   PubMedGoogle Scholar
• Yin Y, Yamashita Y, Noda H, Okafuji T, Go MJ, Tanaka H. 2004. EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurosci Res 48:285–296
   PubMed Web of Science ®Google Scholar
• Yuan W, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J. 2012. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma 59:105–113
   PubMed Web of Science ®Google Scholar
• Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. 1999. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629–638
   PubMedGoogle Scholar
• Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. 2009. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39
   PubMed Web of Science ®Google Scholar
• Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, et al. 2010. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70:299–308
   PubMed Web of Science ®Google Scholar